S1PR1 and B-cell chronic lymphocytic leukemia: In contrast, such migration is blocked by CLL cell treatment with ibrutinib, an effect that is reported to be mediated by inhibition of chemokine receptor-induced integrin α4β1 activation27–29, and a compound which we have shown neither influences expression of S1PR1 nor CLL cell migration to S1P27.